Pulse Biosciences, Inc. (PLSE) Reports Q4 Loss of $0.54/sh

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. INTC
2. AMZN
3. COIN
4. RDDT
5. PINS
6. FSLR
7. DASH
8. SYK
9. MA
10. FND

Go back to Pulse Biosciences, Inc. (PLSE) Reports Q4 Loss of $0.54/sh

Pulse Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results

February 22, 2021 4:05 PM EST

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing its Nano-Pulse Stimulation (NPS) technology, today announced financial results for the fourth quarter and full year ended December 31, 2020.

Recent Highlights

Received U.S. Food and Drug Administration (FDA) clearance for the CellFX® System for dermatologic procedures requiring ablation and resurfacing of the skin Received CE mark approval for the CellFX System Initiated the CellFX System Controlled Launch program in the U.S. and Europe, including system implementations and completion of the first... More